Alex is an experienced patent attorney with a diverse client base. He provides leading pharmaceutical companies with strategic legal and business advice pertaining to patent prosecution and patent portfolio management. Alex regularly evaluates issues related to patentability and freedom-to-operate. He holds a PhD in organic chemistry from UC Berkeley and focuses primarily on chemistry pertaining to pharmaceuticals, chemicals, materials, and polymers.
Alex is a registered patent attorney who advises clients on matters pertaining to patent prosecution and patent portfolio management. He provides guidance to clients on developing portfolios for critical assets, and helps devise strategies for expanding protections on existing portfolios. Alex regularly performs prior art, landscape, and freedom-to-operate searches as part of his evaluation of patentability and freedom-to-operate issues, and prepares patentability, validity, and freedom-to-operate opinions for portfolio analyses and investment due diligence.
Alex has prepared and prosecuted patent applications for both public institutions and private pharmaceutical companies. In addition, he has managed patent portfolios for a variety of clients, prepared patentability and freedom-to-operate opinions for venture capital groups, and assisted in the development of a new product in the personalized medicine space for a medical technology provider. Although his practice focuses primarily on chemistry — including pharmaceuticals, chemicals (organic, inorganic, and organometallic), materials, and polymers — Alex also has experience with biotechnology (assays, PCR), polymeric drug delivery methods, fuel cell materials, and nanotechnology.
Alex’s PhD research focused on the rational design of new materials for nanometer scale imaging, and included the design and synthesis of small molecules and functional macromolecules for use in studies for nanoscale patterning.
viewpoints
A Later-Filed, Later-Expiring Unrelated Patent is Not a Proper Reference Patent for an Obviousness-Type Double Patenting Rejection
November 20, 2024 | Blog | By Alex Trimble, PhD
The New Rubric for Obviousness-Type Double Patenting
October 21, 2024 | | By Alex Trimble, PhD
Federal Circuit Affirms Obviousness of Rifaximin Polymorph Patents and Denial of Motion to Modify Judgment After Post-Trial Patented Indication Carve Out
April 25, 2024 | Blog | By Joe Rutkowski, Peter Cuomo, Thomas Wintner, Adam Samansky, Alex Trimble, PhD
In a precedential opinion issued on April 11, 2024 in Salix Pharmaceuticals, Ltd. v. Norwich Pharmaceuticals Inc., Nos. 22-2153, 23-1952, the U.S. Court of Appeals for the Federal Circuit affirmed the U.S. District Court for the District of Delaware’s decision holding claims directed to polymorphic form “β” of rifaximin invalid as obvious.
A Continuation Application is an Implicit Admission of Obviousness-Type Double Patenting When Filed from a Parent Patent
March 19, 2024 | Blog | By Alex Trimble, PhD
Filing a continuation application from a parent patent is an implicit admission that obviousness-type double patenting (ODP) applies to the resulting continuation patent. A Terminal Disclaimer in the continuation patent over the parent patent is thus necessary to avoid the public policy concerns underlying ODP.
Practical Guidelines for Avoiding Patent Term Adjustment Penalty
March 1, 2024 | Blog | By Alex Trimble, PhD
Why Pharma Companies Should File Patents Later In The R&D Process
July 25, 2023 | Blog | By Alex Trimble, PhD
Filing a pharmaceutical patent application after the start of Phase II clinical trials can maximize the patent’s value and exclusivity period. In an article also published in IAM magazine, Mintz Member Alex Trimble talks about delayed filing options and how to avoid invalidation of the patent based on its “public use” during the clinical trial or published information about the trial.
EXCLUSIVE RIGHTS: Intellectual Property — Don’t Get Caught Double Patenting!
October 21, 2021 | Podcast | By Alex Trimble, PhD
Canada Institutes Certificates of Supplementary Protection for Approved Drug Products
October 6, 2017 | Blog | By Alex Trimble, PhD
News & Press
The Best Lawyers in America 2025 Recognizes 184 Mintz Attorneys across 56 Practice Areas
August 15, 2024
187 Mintz attorneys have been recognized by Best Lawyers® in the 2025 edition of The Best Lawyers in America©. Notably, three Mintz attorneys received 2025 “Lawyer of the Year” awards, and 64 firm attorneys were included in the 2025 edition of Best Lawyers: Ones to Watch.
Mintz is pleased to announce that 120 firm attorneys have been recognized as leaders by Best Lawyers® in the 2024 edition of The Best Lawyers in America©.
Why Pharma Companies Should File Clinical Trial-Related Patents Later In The R&D Process
March 31, 2023
As part of its Life Sciences special, IAM published an article authored by Member Alex Trimble discussing when in the research and development process pharma companies should file clinical trial-related patents.
Best Lawyers® recognized 108 firm attorneys in the 2023 edition of The Best Lawyers in America©. Notably, two Mintz attorneys – Poonam Patidar and Scott M. Stanton – received 2023 “Lawyer of the Year” awards, and 28 firm attorneys were included in the inaugural edition of Best Lawyers: Ones to Watch.
Events & Speaking
Panel - Beyond the Obvious: Novelty, Non-obviousness, and the Inventive Step in Polymorph Patents and Beyond
LSPN North America Fall 2024
Hyatt Regency, San Francisco
Prioritizing Your Patent Filings: Business and Legal Considerations
ACC, San Francisco-Life Sciences CLE Conference
Virtual
Publications
Author, Why pharma companies should file clinical trial-related patents later in the R&D process, IAM, (March 2023)
Read less
Alex is an experienced patent attorney with a diverse client base. He provides leading pharmaceutical companies with strategic legal and business advice pertaining to patent prosecution and patent portfolio management. Alex regularly evaluates issues related to patentability and freedom-to-operate. He holds a PhD in organic chemistry from UC Berkeley and focuses primarily on chemistry pertaining to pharmaceuticals, chemicals, materials, and polymers.
Recognition & Awards
Best Lawyers in America: Biotechnology and Life Sciences Practice (2023 – 2025)
Alex is an experienced patent attorney with a diverse client base. He provides leading pharmaceutical companies with strategic legal and business advice pertaining to patent prosecution and patent portfolio management. Alex regularly evaluates issues related to patentability and freedom-to-operate. He holds a PhD in organic chemistry from UC Berkeley and focuses primarily on chemistry pertaining to pharmaceuticals, chemicals, materials, and polymers.
Involvement
- Member, American Chemical Society
- Member, California Bar Association